Parmtrade FZCO – Trademark Portfolio
Entity Type: 16
Parmtrade FZCO holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 10 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 4 Nice Classification classes. Currently, 8 trademarks are registered and 5 are pending. Notable registered marks include BANDOO, DODAILY, EMSENSE, VITARAY, and DEOFRISK. The owner is based in Dubai.
Dubai Silicon Oasis, DDP, Building A1
Dubai , AE
Showing of trademarks Trademarks
Trademark Classifications
Parmtrade FZCO's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Parmtrade FZCO have?
Parmtrade FZCO has 16 U.S. trademarks filed with the USPTO. Of these, 8 registered, 5 pending, 3 abandoned.
What trademark classes does Parmtrade FZCO file in?
Parmtrade FZCO files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 10 (Medical Apparatus), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Parmtrade FZCO's most well-known trademarks?
Parmtrade FZCO's registered trademark portfolio includes well-known marks such as BANDOO, DODAILY, EMSENSE, VITARAY, and DEOFRISK. These are among 8 currently registered trademarks in the portfolio.
What is Parmtrade FZCO's trademark registration success rate?
Parmtrade FZCO has a 73% trademark registration rate, with 8 out of 11 resolved applications resulting in successful registration. Currently, 5 applications are pending review.